The Johns Hopkins Translational Science Team (JH-TST) for the NCI Experimental Therapeutics Clinical Trials Network (ET-CTN) will evaluate promising new therapies for patients with malignant disease in a clinically efficient, regulatory compliant and scientifically rigorous collaborative research environment. The molecular characterization of all enrolled patients will be standard. Building upon a strong foundation in th conduct of early phase trials, we have assembled an interactive and interdisciplinary Team from a pool of investigators involved in SPORE, R01, P01, and U01 projects. Our JH-TST has six aims:
Aim1 -To contribute collaboratively and actively in the ET-CTN as a team member.;
Aim 2 -To conduct informative Phase l/lI clinical trials of novel anti-cancer agents in a timely manner.;
Aim 3 -To collaborate with ET-CTN teams to perform detailed molecular characterization of novel anti-cancer agents and explore pharmacokinetic (PK) - pharmacodynamic (imaging and biomarkers) and pharmacogenomic relationships between relevant indices of drug exposure and clinical, toxicological, and biological endpoints.;
Aim 4 -To implement correlative and biological laboratory studies in """"""""proof of drug mechanism"""""""" early phase studies in order to enhance our understanding of determinants of toxicity and response that, combined with assessment of PK relationships, will be used to select drug dose and schedule for further evaluation.;
Aim 5 -To maintain a clinical trial infrastructure that is current and compliant with regulatory standards that assure quality care to patients enrolled on early phase clinical trials a well as provide prompt data sharing with other investigators and interested parties.;and.
Aim 6 -To train the next generation of investigators in drug development. Through these aims and with a focus on team science and collaboration across UM1 participants, the JH-TST is committed to the success of the ET-CTN. Our Team has averaged 120 patients/year on NCI UOl supported trials. We anticipate that we will easily meet the required 50 patients/year accrual. We will support the Early Phase CIRB and adhere to other metrics of the Operational Efficiency Working Group to assure timely activation, completion, and dissemination of our findings.
Our Team will continue its long-standing contribution to the drug development efforts of the NCI through UM1-based project teams. We anticipate that our contribution within the Network will impact the clinical care of cancer patients. We anticipate enhanced interactions with the National Clinical Trials Network (NCTN) through our ECOG-ACRIN affiliation to bring forward successes from the efforts of the ET-CTN.
|Mehrotra, Shailly; Gopalakrishnan, Mathangi; Gobburu, Jogarao et al. (2017) Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies. Clin Cancer Res 23:6421-6429|
|Connolly, Roisin M; Li, Huili; Jankowitz, Rachel C et al. (2017) Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res 23:2691-2701|
|Gojo, Ivana; Beumer, Jan H; Pratz, Keith W et al. (2017) A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. Clin Cancer Res 23:697-706|
|Baik, Christina S; Rubin, Eric H; Forde, Patrick M et al. (2017) Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Clin Cancer Res 23:4992-5002|
|Anagnostou, Valsamo; Yarchoan, Mark; Hansen, Aaron R et al. (2017) Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clin Cancer Res 23:4959-4969|
|Connolly, Roisin M; Rudek, Michelle A; Piekarz, Richard (2017) Entinostat: a promising treatment option for patients with advanced breast cancer. Future Oncol 13:1137-1148|
|LaCerte, Carl; Ivaturi, Vijay; Gobburu, Joga et al. (2017) Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. Clin Cancer Res 23:3592-3600|
|Rebechi, Melanie T; Pratz, Keith W (2017) Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression. Leuk Lymphoma 58:1-11|
|Webster, Jonathan A; Tibes, Raoul; Morris, Larry et al. (2017) Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res 61:108-116|
|Pratz, Keith W; Rudek, Michelle A; Gojo, Ivana et al. (2017) A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia. Clin Cancer Res 23:899-907|
Showing the most recent 10 out of 37 publications